1137 related articles for article (PubMed ID: 25043012)
1. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide.
Fischer ES; Böhm K; Lydeard JR; Yang H; Stadler MB; Cavadini S; Nagel J; Serluca F; Acker V; Lingaraju GM; Tichkule RB; Schebesta M; Forrester WC; Schirle M; Hassiepen U; Ottl J; Hild M; Beckwith RE; Harper JW; Jenkins JL; Thomä NH
Nature; 2014 Aug; 512(7512):49-53. PubMed ID: 25043012
[TBL] [Abstract][Full Text] [Related]
2. Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase.
Petzold G; Fischer ES; Thomä NH
Nature; 2016 Apr; 532(7597):127-30. PubMed ID: 26909574
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R
Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678
[TBL] [Abstract][Full Text] [Related]
4. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs.
Chamberlain PP; Lopez-Girona A; Miller K; Carmel G; Pagarigan B; Chie-Leon B; Rychak E; Corral LG; Ren YJ; Wang M; Riley M; Delker SL; Ito T; Ando H; Mori T; Hirano Y; Handa H; Hakoshima T; Daniel TO; Cathers BE
Nat Struct Mol Biol; 2014 Sep; 21(9):803-9. PubMed ID: 25108355
[TBL] [Abstract][Full Text] [Related]
5. pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4
An J; Ponthier CM; Sack R; Seebacher J; Stadler MB; Donovan KA; Fischer ES
Nat Commun; 2017 May; 8():15398. PubMed ID: 28530236
[TBL] [Abstract][Full Text] [Related]
6. USP15 antagonizes CRL4
Nguyen TV
Proc Natl Acad Sci U S A; 2021 Oct; 118(40):. PubMed ID: 34583995
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of the SALL4-pomalidomide-cereblon-DDB1 complex.
Matyskiela ME; Clayton T; Zheng X; Mayne C; Tran E; Carpenter A; Pagarigan B; McDonald J; Rolfe M; Hamann LG; Lu G; Chamberlain PP
Nat Struct Mol Biol; 2020 Apr; 27(4):319-322. PubMed ID: 32251415
[TBL] [Abstract][Full Text] [Related]
8. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase.
Matyskiela ME; Lu G; Ito T; Pagarigan B; Lu CC; Miller K; Fang W; Wang NY; Nguyen D; Houston J; Carmel G; Tran T; Riley M; Nosaka L; Lander GC; Gaidarova S; Xu S; Ruchelman AL; Handa H; Carmichael J; Daniel TO; Cathers BE; Lopez-Girona A; Chamberlain PP
Nature; 2016 Jul; 535(7611):252-7. PubMed ID: 27338790
[TBL] [Abstract][Full Text] [Related]
9. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon.
Akuffo AA; Alontaga AY; Metcalf R; Beatty MS; Becker A; McDaniel JM; Hesterberg RS; Goodheart WE; Gunawan S; Ayaz M; Yang Y; Karim MR; Orobello ME; Daniel K; Guida W; Yoder JA; Rajadhyaksha AM; Schönbrunn E; Lawrence HR; Lawrence NJ; Epling-Burnette PK
J Biol Chem; 2018 Apr; 293(16):6187-6200. PubMed ID: 29449372
[TBL] [Abstract][Full Text] [Related]
10. UBE2G1 governs the destruction of cereblon neomorphic substrates.
Lu G; Weng S; Matyskiela M; Zheng X; Fang W; Wood S; Surka C; Mizukoshi R; Lu CC; Mendy D; Jang IS; Wang K; Marella M; Couto S; Cathers B; Carmichael J; Chamberlain P; Rolfe M
Elife; 2018 Sep; 7():. PubMed ID: 30234487
[TBL] [Abstract][Full Text] [Related]
11. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G
FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201
[TBL] [Abstract][Full Text] [Related]
12. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J
Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626
[TBL] [Abstract][Full Text] [Related]
13. Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs.
Lindner S; Steinebach C; Kehm H; Mangold M; Gütschow M; Krönke J
J Vis Exp; 2019 May; (147):. PubMed ID: 31157769
[TBL] [Abstract][Full Text] [Related]
14. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN.
Sievers QL; Petzold G; Bunker RD; Renneville A; Słabicki M; Liddicoat BJ; Abdulrahman W; Mikkelsen T; Ebert BL; Thomä NH
Science; 2018 Nov; 362(6414):. PubMed ID: 30385546
[TBL] [Abstract][Full Text] [Related]
15. [Discovery of the target for immunomodulatory drugs (IMiDs)].
Ito T; Ando H; Handa H
Rinsho Ketsueki; 2016 May; 57(5):556-62. PubMed ID: 27263779
[TBL] [Abstract][Full Text] [Related]
16. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.
Lopez-Girona A; Mendy D; Ito T; Miller K; Gandhi AK; Kang J; Karasawa S; Carmel G; Jackson P; Abbasian M; Mahmoudi A; Cathers B; Rychak E; Gaidarova S; Chen R; Schafer PH; Handa H; Daniel TO; Evans JF; Chopra R
Leukemia; 2012 Nov; 26(11):2326-35. PubMed ID: 22552008
[TBL] [Abstract][Full Text] [Related]
17. PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates.
Shimizu N; Asatsuma-Okumura T; Yamamoto J; Yamaguchi Y; Handa H; Ito T
Commun Biol; 2021 Nov; 4(1):1277. PubMed ID: 34764413
[TBL] [Abstract][Full Text] [Related]
18. Homo-PROTACs for the Chemical Knockdown of Cereblon.
Steinebach C; Lindner S; Udeshi ND; Mani DC; Kehm H; Köpff S; Carr SA; Gütschow M; Krönke J
ACS Chem Biol; 2018 Sep; 13(9):2771-2782. PubMed ID: 30118587
[TBL] [Abstract][Full Text] [Related]
19. The interacting domains in cereblon differentially modulate the immunomodulatory drug-mediated ubiquitination and degradation of its binding partners.
Tao J; Yang J; Xu G
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):443-449. PubMed ID: 30458989
[TBL] [Abstract][Full Text] [Related]
20. Targeting cereblon in hematologic malignancies.
Fuchs O
Blood Rev; 2023 Jan; 57():100994. PubMed ID: 35933246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
